Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

ALEXANDRIA PANKKIIRILIIKE OYJ: ACQUISITION OF OWN SHARES 20.07.2022

ALEXANDRIA PANKKIIRILIIKE OYJ NOTIFICATION    20.07.2022 at 18:30 EET   ALEXANDRIA PANKKIIRILIIKE OYJ: ACQUISITION OF OWN SHARES 20.07.2022   Date 20.07.2022  Exchange transaction Buy  Share class ALEX  Amount 151  Average price/share 7.7000   EURHighest price/share 7.7000 EURLowest price/share 7.7000 EURTotal price 1,162.70 EUR        The shares held by Alexandria Pankkiiriliike Oyj on 20.07.

FISKARS CORPORATION: ACQUISITION OF OWN SHARES 20.07.2022

Fiskars Corporation   Stock Exchange Release 20.07.2022 at 18:30 EET/EEST   FISKARS CORPORATION: ACQUISITION OF OWN SHARES 20.07.2022   Date 20.07.2022  Exchange transaction Buy  Share class FSKRS  Amount  4,100  Average price/share 18.4333 EURHighest price/share 18.5200 EURLowest price/share 18.1800 EURTotal price 75,576.53 EUR        The shares held by Fiskars Corporation on 20.07.2022:   FSKRS 875,011       On

#22-250 Delisting of Derivatives from NGM

Information about certain derivatives that will be delisted from NGM.For more details, see attached files. For further information concerning this NGM notice please contact NGM Listing department on phone +46 8 566 390 20 or listings@ngm.se Nordic Growth Market NGM AB About NGMNordic Growth Market NGM AB (NGM) is an authorized stock exchange with operations in Sweden, Norway, Denmark and Finland. The exchange is a wholly-owned subsidiary of Boerse Stuttgart, the leading retail exchange in Germany. NGM offers a complete marketplace for exchange traded products and provides a

Scandinavian ChemoTech announces that TSE™ therapy has been initiated at Ulis Medical Centre in Ukraine

After concluding the training of doctors, nurses and support staff at Ulis Medical Centre in Ukraine last week, the program started today and the first patient was treated.Today the first treatment with Tumour Specific Electroporation - TSE™ was performed at Ulis Medical Centre in Ukraine to treat a woman with invasive squamous cell carcinoma (skin cancer). The therapy was performed with support from ChemoTech’s application team and ChemoTech’s Medical Adviser Dr. Suhail Mufti.   Since the treatment was performed under the intended use of TSE™, it is part of the general TSE™-program

New patent approval in Hong Kong for Episurf Medical

The Intellectual Property Department (IPD) of Hong Kong has granted another patent for Episurf Medical (NASDAQ: EPIS B). The patent, entitled “Tools for assisting in osteotomy procedures, and methods for designing osteotomy tools”, relates to surgical instruments in Episurf Medical’s Episealer® Talus technology for the ankle. "The patent covers Episurf’s individualised osteotomy guide, developed for optimised clinical outcomes when treating difficult to reach ankle lesions. This device is an important part of the Episealer® Talus technology which is available in the Hong Kong market”,

/Finspång’s healthcare center-original art and architecture with a long lifespan

Beautiful architecture and inspiring design characterize Finspång’s new healthcare center in Sweden, where unique art can be found among the common areas but also on the walls of the building structure. The project has received the award Miljöbyggnad Silver, where they have worked a lot on a construction technology that has a long lifespan. Energy savings have been made through solar panels that are located on the roof and an outstanding glass and aluminum facade can be found in the health center’s courtyards, among other places. Through GlasLindberg, SAPA has delivered facades and doors in

FDA announces an Oncologic Drugs Advisory Committee meeting to discuss benefit/risk profile of Oncopeptides’ Pepaxto

STOCKHOLM — July 20, 2022 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hematological diseases, today announces that the US Food and Drug Administration (FDA), has announced a forthcoming public advisory meeting of the Oncologic Drugs Advisory Committee (ODAC), on September 22, 2022, to discuss the benefit/risk of Pepaxto[®] (melphalan flufenamide).On January 21 Oncopeptides announced that it has rescinded the October 22, 2021, letter requesting a voluntary withdrawal of the New Drug Application (

Nokian Tyres will publish its Half Year Financial Report January−June 2022 on August 2, 2022

Nokian Tyres plc Press Release July 20, 2022 at 3:55 p.m.  Nokian Tyres will publish its Half Year Financial Report January−June 2022 on August 2, 2022 approximately at 2:00 p.m. EET. After publication, the release will be available on the company's website at www.nokiantyres.com/company/investors/.   Conference call   A conference call for investors, analysts and media will be held on August 2 at 3:00 p.m. EET. In the call, President and CEO Jukka Moisio and CFO Teemu Kangas-Kärki will present the financial results.   To participate, please dial in 5−10 minutes

Intervacc receives order for Strangvac, a vaccine against the equine disease strangles, from the Dechra Pharmaceuticals PLC Group for launch in selected European countries

Stockholm, July 20th 2022 - Intervacc AB (publ) announces today that the company has received an order for the equivalent of approximately SEK 3 million from Dechra. The order concerns the delivery of Strangvac, a vaccine against the highly contagious and serious infectious disease equine strangles, which is endemic across Europe. The order, which contains vaccine vials for regions including the UK, Germany and France, is for delivery during July 2022 and used for launch in selected European countries. “This order from our distribution partner Dechra, will facilitate the launch of

Strangvac, a vaccine against equine strangles released for sales in the UK

Stockholm, July 20th, 2022 - Intervacc AB (publ) announces today that the first batch of Strangvac for sale in the UK has been released. “The first batch of Strangvac for the UK market has now been released. This means that sales of Strangvac in the UK can begin shortly”, explains Andreas Johansson, Logistics Manager at Intervacc. "Strangvac is approved for sale and marketing in the EU as well as the UK, Norway and Iceland, and has been launched in Sweden and Denmark. The UK is expected to be one of the largest markets in Europe for vaccines against the highly contagious infectious

Camping, caravanning & rail travel top Readly's holiday searches

                                         Are you travelling this summer and looking for something to entertain and inspire you? Whether you are holidaying overseas or staying local this year, Readly , the digital magazine and newspaper subscription app, is the perfect holiday read. And with a sizzling summer offer of 1 month free unlimited reading to thousands of magazines and newspapers, you won’t be short of something to read!  Research shows that over half of us (53 percent) will travel or take a holiday this summer. Whilst almost a third (27

Trophy Games changes certified advisor to Norden CEF

. Company Announcement No. 7-2022 Copenhagen, 20. July 2022 . TROPHY GAMES Development A/S (Nasdaq First North Growth Market Denmark: TGAMES) has entered into a Certified Advisor Agreement with Norden CEF. The Agreement will be effective as of August 1st, 2022 and has been concluded with reference to Nasdaq’s Member rules, which are available on Nasdaq’s website.   Contact Information TROPHY GAMES Development A/S Søren Gleie, CEO Office (+45) 7172 7573 Email: soren@trophy-games.com Mikkel Bryggers Gade 4, 2. floor, 1460 Copenhagen K, Denmark .

Elkem ASA – Exercise of share options under share incentive programme

Oslo, 20 July 2022 Option holders under Elkem ASA's ("Elkem" or the "Company", OSE ticker code: "ELK") share incentive programme have today exercised 20,000 options at an exercise price of NOK 19.10 per share. The exercised options will be settled by delivery of Elkem’s shareholding of own shares. Following the transfer, the Company will hold 5,435,000 own shares. The exercised options have been granted in accordance with the Company's share option programme described in the Company's latest annual financial statement. This information is subject to the disclosure requirements

SOFTSWISS Jackpot Aggregator: Half of Players Increase Average Bet Sum After Joining Jackpot Campaigns

Up to 50% of players increase their average bet sum, and almost 70% of casino players make more daily wagers after participating in jackpot campaigns. SOFTSWISS shares the first results from clients connected to the Jackpot Aggregator, the company's latest iGaming innovative product.Launched in October 2021, the Jackpot Aggregator  is an iGaming business tool for player acquisition, engagement, and retention.  To analyse the influence of jackpot campaigns on key casino

Fuud completes acquisition of GI-Boxen and Foodbox

STOCKHOLM, July 20, 2022 12.00 CEST On March 28, 2022, FUUD AB (publ) (“Fuud” or “the Company”) entered into a conditional agreement to acquire 100 percent of the shares in GI-Boxen Sweden AB (“GI-Boxen”) and Foodbox Scandinavia AB (“Foodbox”). In accordance with the Supplementary Agreement entered into on May 20, 2022 (the “Supplementary Agreement”), the total initial purchase price of SEK 55 million will be paid through 168,586,956 newly issued shares in Fuud at a subscription price of SEK 0.23 per share, corresponding to a total of approximately SEK 38.78 million, partly in the form of

Sapphire BidCo Ltd to commence redemption proceedings in respect of the remaining minority shares in Basware Corporation

Basware Corporation, stock exchange release, 20 July 2022 at 12.45 p.m. EESTNOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND OR SOUTH AFRICA OR IN ANY OTHER JURISDICTION IN WHICH THE TENDER OFFER WOULD BE PROHIBITED BY APPLICABLE LAW. On 27 June 2022, Sapphire BidCo Ltd (the “Offeror”) announced that it will complete the voluntary recommended public cash tender offer to acquire all of the issued and outstanding shares in Basware Corporation (“Basware” or the “Company”) that are not held

Epiroc interim report Q2 2022

•    Orders received increased 21% to MSEK 13 377 (11 070), organic increase of 6%. Excluding Russia, the organic order growth was 18%.•    Revenues increased 22% to MSEK 11 868 (9 733), organic increase of 9%.•    Operating profit increased 9% to MSEK 2 381 (2 182), corresponding to a margin of 20.1% (22.4). •    Items affecting comparability were MSEK -420 (-15), including a provision of MSEK -400 related to Russia.* •    Adjusted operating profit increased 27% to MSEK 2 801 (2 197), corresponding to a margin of 23.6% (22.6).•    Basic earnings per share were SEK 1.47 (1.40).•

Half-year Financial Report of KONE Corporation for January–June 2022

KONE Corporation, stock exchange release, July 20, 2022 at 12.30 p.m. EEST Half-year Financial Report of KONE Corporation for January–June 2022 Second quarter strongly impacted by China COVID-19 lockdowns, favorable development in other regions April–June 2022 · Orders received grew by 8.2% to EUR 2,609.0 (4–6/2021: 2,410.7) million. At comparable exchange rates, orders grew by 0.6%. · Sales declined by 9.1% to EUR 2,555.1 (2,810.8) million. At comparable exchange rates, sales declined by 15.2%. · Operating income (EBIT) was EUR 189.0 (367.1) million or 7.4 % (13.1 %) of

Announcing 2024 IFPA Conference President and Theme

The 7[th] IFPA Conference  will be held June 27-29, 2024 in Stockholm Sweden. Dermatologists, rheumatologists, and experts from around the world will gather to share breakthroughs in psoriatic disease research.Professor April Armstrong will lead the scientific program as the 2024 Conference President and Chair of the Scientific Executive Committee. Professor Armstrong is Associate Dean of Clinical Research at Keck School of Medicine at the University of Southern California. She will be supported by Professor Ulrich Mrowietz, Co-Chair in

Invitation to presentation of MilDef´s Q2 interim report 2022, on July 28

MilDef, the nordic region's leading supplier of tactical IT, software solutions and services, will publish its second quarter results for 2022 on July 28, at 08:00 am CET.A conference (on Teams) for investors, analysts and media will be held at 10.00-10.45 CET that same day. The report will be presented by Björn Karlsson, CEO and Daniel Ljunggren, CFO.   The presentation will be held in English and is concluded with a Q&A session. Presentation material will be made available on www.mildef.com the same morning. Notification is not required for participation in the conference call but

MilDef's CEO increases his holding in the company

Through the call options issued in 2015, MilDef's CEO Björn Karlsson has today increased his holding by 549,000 shares.Previous holdings of 1,551,821 shares represented 4.26 percent of the shares in the company. Following the acquisition of an additional 549,000 shares, his holding amounts to 2,100,821 shares, corresponding to 5.77 percent of the total number of shares in MilDef Group. The information was submitted for publication, through the agency of the contact persons set out below, at 10:00 CET on July 20, 2022.

Save the date – AAK’s Capital Market Day November 29, 2022

AAK’s Capital Market Day 2022 is scheduled for November 29.  The intention is to host a physical event in Stockholm, Sweden, at Grand Hôtel, although this might change depending on potential Covid-19-related restrictions. The official program will start around lunch and end no later than 5:00 p.m. CET.  More information will follow in the official invitation, which will be sent out during the fall.     For more information, please contact:Johan HolmqvistActing Head of IR and Corporate CommunicationsMobile: +46 708 37 66 77E-mail: johan.holmqvist@aak.com   The

There are no items matching the current filter
There are no more items matching the current filter
Back to top